Arrowhead Pharma just crashed the obesity drug party—its new RNAi therapy, when paired with Lilly’s tirzepatide, doubled the weight loss seen with tirzepatide alone in early trials. Not only that, but it slashed more of the stubborn visceral and liver fat that really matters for metabolic health. The catch? It’s early days and only a handful of patients, but Wall Street is already hyped. Could this be the next big thing in weight loss meds? #Fitness #weightloss #obesity